Express News | Nurix Therapeutics Presents Preclinical Data From Two Autoimmune and Inflammatory Disease Programs, Nx-5948 and Gs-6791, at Acr Convergence 2024
Nurix Therapeutics Down Over 10%, on Pace for Largest Percent Decrease Since October 2023 -- Data Talk
Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 25% Price Boost Is Out Of Tune With Revenues
Needham Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $29
Nurix Therapeutics Price Target Maintained With a $29.00/Share by Needham
Promising Efficacy and Safety of Nurix Therapeutics' NX-5948 Justifies Buy Rating
Bigmoney Dreamer : Already 500% current year where is yearly bottom of strong buy potential
Bigmoney Dreamer : Time to make separate watchlist of strong buys so get better cost price for less red days